摘要
目的探讨选择性胆碱能受体拮抗剂辅助治疗老年重度慢性阻塞性肺疾病(COPD)临床疗效。方法 100例老年重度慢性阻塞性肺疾病患者,以随机数字表法分为对照组和联合组,每组50例。对照组单用沙美特罗替卡松治疗,联合组则在对照组基础上加用噻托溴铵辅助治疗。比较两组患者近期疗效、不良反应发生情况及治疗前后的呼吸困难症状评分、用力肺活量(FVC)、第1秒钟用力呼吸容积(FEV1)及FEV1占预计值百分比(FEV1%)水平。结果联合组患者的近期治疗总有效率96.00%显著高于对照组的78.00%,差异具有统计学意义(P<0.05)。治疗后,两组患者的呼吸困难症状评分、FVC、FEV1及FEV1%水平均显著优于治疗前,且联合组患者呼吸困难症状评分、FVC、FEV1及FEV1%水平均显著优于对照组,差异具有统计学意义(P<0.05)。两组患者不良反应发生率比较差异无统计学意义(P>0.05)。结论选择性胆碱能受体拮抗剂辅助治疗老年重度慢性阻塞性肺疾病可有效减轻相关症状体征,提高肺部通气功能,且未加重药物不良反应。
Objective To discuss the clinical efficacy of selective cholinergic receptor antagonist in the treatment of severe chronic obstructive pulmonary disease（COPD） in the elderly. Methods A total of 100 elderly patients with severe chronic obstructive pulmonary disease were divided by random number table method into control group and combined group, with 50 cases in each group. The control group was treated with salmeterol/fluticasone, and the combined group was treated with tiotropium bromide on the basis of the control group. Comparison were made on short-term efficacy, occurrence of adverse reactions, and respiratory dyspnea symptom score, forced vital capacity（FVC）, forced breathing volume in 1 second（FEV1） and FEV1 percentage of expected value（FEV1%） before and after treatment between the two groups. Results The combined group had obviously higher total effective rate of short-term treatment as 96.00% than 78.00% in the control group, and the difference was statistically significant（P〈0.05）. After treatment, both groups had significantly better respiratory dyspnea symptom score, FVC, FEV1 and FEV1% level than before treatment, and the combined group had obviously better respiratory dyspnea symptom score, FVC, FEV1 and FEV1% level than the control group. Their difference was statistically significant（P〈0.05）. Both groups had no statistically significant difference in incidence of adverse reactions（P〉0.05）. Conclusion Selective cholinergic receptor antagonist can effectively reduce related symptoms and signs of chronic obstructive pulmonary disease in the elderly and improve pulmonary ventilation function without aggravating of adverse drug reactions.
作者
张希
ZHANG Xi.(Department of Respiratory Medicine, Dianjiang Hospital of Traditional Chinese Medicine, Chongqing 408300, Chin)
出处
《中国实用医药》
2018年第9期1-3,共3页
China Practical Medicine
关键词
选择性胆碱能受体拮抗剂
慢性阻塞性肺疾病
老年
疗效
安全性
Selective cholinergic receptor antagonist
Chronic obstructive pulmonary disease
Elderly
Efficacy
Safety
